FIGURE 2
FROM:
Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector
Ming-Zhu Zhao, Naosuke Nonoguchi, Naokado Ikeda, Takuji Watanabe, Daisuke Furutama, Daisuke Miyazawa, Hiroshi Funakoshi, Yoshinaga Kajimoto, Toshikazu Nakamura, Mari Dezawa, Masa-Aki Shibata, Yoshinori Otsuki, Robert S Coffin, Wei-Dong Liu, Toshihiko Kuroiwa and Shin-Ichi Miyatake
BACK TO ARTICLEFigure 2.
Behavioral functional test (mNSS) before and after MCAO. Groups 1 and 5: treated with PBS; groups 2 and 6: treated with MSC-only; group 3: treated with MSC-GFP; groups 4 and 7: treated with MSC-HGF (n=6 per group). The rats of groups 2 to 7 received 1.0 
106 cells via intracerebral transplantion in 10 
l PBS. (A) Groups 2 to 4 received transplantation 2 h after MCAO (superacute phase); (B) groups 4 to 7 received transplantation 24 h after MCAO (acute phase). (C) Lists the mNSS on day 14 of groups 1, 2, 4, 5, 6, and 7, showing that the significant neurological recovery among 6 groups while under the comparing condition is only the different therapeutic time phase. Significant functional recovery was detected in the MSC-HGF group compared with the other groups. Data are presented as means
s.d.